The role of melatonin in patients with chronic kidney disease undergoing haemodialysis

Journal of Renal Care

Volumn 38, Issue 2, 2012, Pages 86-92

  Aperis, Georgios ^a   Prakash, Preeth ^b   Paliouras, Christos ^a   Papakonstantinou, Nikolaos ^a   Alivanis, Polichronis ^a  

^a General Hospital of Rhodes   (Greece)

^b Northern Lincolnshire and Goole Hospitals NHS Foundation Trust   (United Kingdom)

Author keywords

Chronic kidney disease; Haemodialysis; Melatonin; Peritoneal dialysis; Physiology of melatonin; Renal failure

Indexed keywords

MELATONIN;

ARTICLE; BLOOD; CHRONIC KIDNEY FAILURE; CIRCADIAN RHYTHM; CIRCADIAN RHYTHM SLEEP DISORDER; DOSE RESPONSE; DRUG ADMINISTRATION; HUMAN; NURSING; PHYSIOLOGY; RENAL REPLACEMENT THERAPY;

CIRCADIAN RHYTHM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMANS; KIDNEY FAILURE, CHRONIC; MELATONIN; RENAL DIALYSIS; SLEEP DISORDERS, CIRCADIAN RHYTHM;

EID: 84860850923     PISSN: 17556678     EISSN: 17556686     Source Type: Journal    
DOI: 10.1111/j.1755-6686.2012.00267.x     Document Type: Article

References (46)

1. Akerstedt T., Froberg J.A. & Friberg Y. (1979). Melatonin excretion, body temperature and subjective arousal during 64 h of sleep deprivation. Psychoneuroendocrinology 4, 219-225.
2. Barrett B.J., Vavasour H.M., Major A., et al (1990). Clinical and psychological correlates of somatic symptoms in patients on dialysis. Nephron 55, 10-15.
3. Bro S., Bjorner J.B. & Tofte-Jensen P., et al (1999). A prospective, randomized multicenter study comparing APD and CAPD. Peritoneal Dialysis International 19, 526-533.
4. Bubenik G.A. Gastrointestinal melatonin: localization, function and clinical relevance. (2002). Digestive Diseases and Sciences 47, 2336-2348.
5. Buck M.L. (2003). The use of melatonin in children with sleep disturbances. Pediatric Pharmacology 9, Available at: (accessed 18/04/2011).
6. Cardinali D.P., Ladizesky M.G. & Boggio V. (2003). Melatonin effects on bone: experimental facts and clinical perspectives. Journal of Pineal Research 34, 81-87.
7. Champier J., Claustrat B. & Besancon R. (1997). Evidence for trypto-phan hydroxylase and hydroxyl-indol-O-methyl-transferase mRNAs in human blood platelets. Life Sciences 60, 2191-2197.
8. Claustrat B., Brun J. & Chazot G. (2005). The basic physiology and pathophysiology of melatonin. Sleep Medicine Review 9, 11-24.
9. de Almeida E.A., Di Mascio P. & Harumi T. (2011). Measurement of melatonin in body fluids: standards, protocols and procedures. Childs Nervous System 27, 879-891.
10. DerMarderosian A. (ed). (1996). Melatonin. In: The Review of Natural Products. St. Louis : Facts and Conparisons, Inc.
11. De Vecchi A., Finazzi S. & Padalino R. (2000). Sleep disorders in peritoneal and haemodialysis patients as assessed by a self-administered questionnaire. International Journal of Artificial Organs 23, 237-242.
12. Ivanenko A., Crabtree V.M. & Tauman R. (2003). Melatonin in children and adolescents with insomnia: a retrospective study. Clinical Pediatrics 42, 51-58.
13. Jan J.E., Freeman R.D. & Fast D.K. (1999). Melatonin treatment of sleep-wake cycle disorders in children and adolescents. Developmental Medicine and Child Neurology 41, 491-500.
14. Kancheva R., Sulková S. & Svára F. (2008). Increase of nocturnal melatonin levels in haemodialysed patients after parathyroidecomy-a pilot study. Physiological Research 57(Suppl.), S181-S185.
15. Karasek M., Szuflet A. & Chrzanowski W. (2002). Circadian serum melatonin profiles in patients suffering from chronic renal failure. Neuroendocrinology Letters 23(Suppl.1), 97-102.
16. Kastrouni M., Sarantopoulou E. & Aperis G., et al (2010). Quality of life of Greek patients with end stage renal disease undergoing haemodialysis. Journal of Renal Care 36, 126-132.
17. Klein D.C. & Moore R.Y. (1979). Pineal N-acetyltransferase and hydroxyindole-o-methyltransferase: control by the retinohypo-thalamic tract and the suprachiasmatic nucleus. Brain Research 174, 245-262.
18. Koch B.C.P., Nagtegaal J.E. & Hagen E.C. (2007a). Impact on sleep when changing from daytime to nocturnal in-hospital hemodial-ysis. In: Sleep-Wake Research in the Neatherlands (eds Ruigt G.S.F., de Boer T., van Kasteel V. et al ), 18th edn, pp. 79-83. Enschede: Print Partners.
19. Koch B.C.P., Nagtegaal J.E. & Hagen E.C. (2007b). Improvement of sleep behavior and melatonin rhythm when changing from daytime to nocturnal in-hospital hemodialysis. Journal of The American Society of Nephrology 18, SU-FC057.
20. Koch B.C.P., Nagtegaal E.J. & Hagen C.E. (2008a). Subjective sleep efficiency of haemodialysis patients. Clinical Nephrology 70, 411-416.
21. Koch B.C.P., Nagtegaal E.J. & Hagen C.E. (2008b). The effects of melatonin on sleep-wake rhythm of daytime haemodialysis patients: a randomized, placebo-controlled cross-over study (EMSCAP study). British Journal of Pharmacology 67, 68-75.
22. Koch B.C.P., Nagtegaal J.E. & Kerkhof G.A. (2009a). Circadian sleep-wake rhythm disturbances in end-stage renal disease. Natural Review Nephrology 5, 407-416.
23. Koch B.C.P., Hagen E.C. & Nagtegaal E. (2009b). Effects of nocturnal haemodialysis on melatonin rhythm and sleep-wake behavior: an uncontrolled trial. American Journal of Kidney Diseases 53, 658-664.
24. Koch B.C.P., Nagtegaal J.E. & Hagen C.E. (2010a). Different melatonin rhythms and sleep-wake rhythms in patients on peritoneal dialysis, daytime hemodialysis and nocturnal hemodialysis. Sleep Medicine 11, 242-246.
25. Koch B.C.P., van der Putten K. & van Someren E.J.W. (2010b). Impairment of endogenous melatonin rhythm is related to the degree of chronic kidney disease (CREAM study). Nephrology Dialysis Transplantation 25, 513-519.
26. Kunz D. & Bes F. (2001). Exogenous melatonin in periodic limb movement disorder: an open clinical trial and a hypothesis. Sleep 24, 183-187.
27. Littner M., Clete A. & Kushida M.D. (2003). Practice parameters for the role of actigraphy in the study of sleep and circadian rhythms: an update for 2002 an American Academy of Sleep Medicine Report, Standards of Practice Committee of the American Academy of Sleep Medicine. Sleep 26, 337-341.
28. Liu C., Fukuhara C. & Wessel III J.H. (2004). Localization of Aa-nat Mrna in the rat retina by fluorescence in situ hybridization and laser capture microdissection. Cell and Tissue Research 315, 197-201.
29. Ludemann P., Zwernemann S. & Lerchl A. (2001). Clearance of melatonin and 6-sulfatoxymelatonin by haemodialysis in patients with end-stage renal disease. Journal of Pineal Research 31, 222-227.
30. Melatonin drug interactions (2011). Available at: (accessed 20/07/2011).
31. Melatonin-oral side effects, medical uses and drug interactions (2011). Available at: (accessed 17/07/2011).
32. Merlino G., Piani A. & Dolso P. (2006). Sleep disorders in patients with end-stage renal disease undergoing dialysis therapy. Nephrology Dialysis Transplantation 21, 184-190.
33. Molzahn A.E., Northcott H.C. & Dossetor J.B. (1997). Quality of life of individuals with end stage renal disease: perceptions of patients, nurses, and physicians. ANNA Journal 24, 325-333.
34. Nagtegaal J.E. (2002). Chronobiological, clinical and pharmacological aspects of melatonin in human circadian rhythm dysfunction. In Treatise on Pineal Gland and Melatonin (eds Haldar C., Singaravel M., Kumar Maitra S.), pp. 461-489. Enfield, USA : Enfield Science Publishers.
35. Nagtegaal J.E., Kerkhof G.A. & Smits M.G. (1998a). Delayed sleep phase syndrome: a placebo-controlled cross-over study on the effects of melatonin administered five hours before the individual dim light melatonin onset. Journal of Sleep Research 7, 135-143.
36. Nagtegaal J.E., Peeters E. & Swart W. (1998b). Correlation between concentrations of melatonin in saliva and serum in patients delayed sleep phase syndrome. Therapeutic Drug Monitoring 20, 181-183.
37. Novak M., Shapiro C.M & Mendelssohn D. (2006). Diagnosis and management of insomnia in dialysis patients. Seminar in Dialysis 19, 25-31.
38. Parker K.P. (2003). Sleep disturbances in dialysis patients. Sleep Medicine Reviews 7, 131-143.
39. Parker K.P., Bliwise D.L. & Rye D.B. (2000). Haemodialysis disrupts basic sleep regulatory mechanisms: building hypotheses. Nursing Research 49, 327-332.
40. Rosen R., Hu D.N. & Perez V. (2009). Urinary 6-sulphatoxymelatonin level in age-related macular degeneration patients. Molecular Vision 15, 1673-1679.
41. Sanker D.J., Soubrane C. & Scatton B. (2007). New perspectives for the treatment of disorders of sleep and arousal. Annales Pharmaceutiques Francaises 65, 268-274.
42. Slominski A., Pisarchik A. & Semak I. (2002). Serotoninergic and melatoninergic systems are fully expressed in human skin. Federation of American Societies for European Journal of Biology 16, 896-898.
43. Soldatos C.R., Dikeos D.G., & Paparrigopoulos T.J. (2000). Athens Insomnia Scale: validation of an instrument based on ICD-10 criteria. Journal of Psychosomatic Research 48, 555-560.
44. Stárka L., Dusková M. & Rácz B., et al (2008). Melatonin negatively correlates with C-peptide after food intake. Physiological Research 57(Suppl.1), S187-S192.
45. Stefulj J., Hortner M. & Ghosh A. (2001). Gene expression of the key enzymes of melatonin synthesis in extrapineal tissues of the rat. Journal of Pineal Research 30, 243-247.
46. Tzischinsky O., Shlitner A. & Lavie P. (1993). The association between the nocturnal deep gate and nocturnal onset of urinary 6-sulfatoxymelatonin. Journal of Biological Rhythms 8, 199-209.